litlas
Log inCreate account

Sumanta K. Pal

Active 2010–2025

265
Papers
27,694
Citations
89
h-index
249
i10-index

Citations

Citations per year for Sumanta K. Pal1956: 1 citations2000: 2 citations2006: 1 citations2007: 2 citations2008: 1 citations2009: 6 citations2010: 4 citations2011: 21 citations2012: 47 citations2013: 57 citations2014: 93 citations2015: 125 citations2016: 156 citations2017: 210 citations2018: 308 citations2019: 1,043 citations2020: 1,530 citations2021: 1,568 citations2022: 1,317 citations2023: 1,034 citations2024: 1,621 citations2025: 895 citations2026: 32 citations1957–1999: no citations, so these years are not shown2001–2005: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,283 citing papers, 24% of this breakdownChina: 1,769 citing papers, 13% of this breakdownItaly: 894 citing papers, 6.5% of this breakdownUnited Kingdom: 772 citing papers, 5.7% of this breakdownFrance: 653 citing papers, 4.8% of this breakdownGermany: 578 citing papers, 4.2% of this breakdownCanada: 503 citing papers, 3.7% of this breakdownSpain: 479 citing papers, 3.5% of this breakdownJapan: 466 citing papers, 3.4% of this breakdownNetherlands: 324 citing papers, 2.4% of this breakdownAustralia: 317 citing papers, 2.3% of this breakdownSouth Korea: 303 citing papers, 2.2% of this breakdown
0%24%Other 24.3%

Institutions

Fields

  • Medicine71.2%
  • Biochemistry, Genetics and Molecular Biology19.5%
  • Immunology and Microbiology5.4%
  • Engineering0.7%
  • Agricultural and Biological Sciences0.7%
  • Neuroscience0.4%
  • Other2.1%

Topics

  • Cancer Immunotherapy and Biomarkers10.4%
  • Renal cell carcinoma treatment7.3%
  • Bladder and Urothelial Cancer Treatments6.5%
  • Ferroptosis and cancer prognosis3.1%
  • Cancer Genomics and Diagnostics2.9%
  • Immunotherapy and Immune Responses2.7%
  • Other67.1%

Coauthors

All papers

Open in search
  1. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

    Authors: Nazlı Dizman, Luís Meza, Paulo Gustavo Bergerot, Marice Alcantara, Tanya B. Dorff, Yung Lyou, Paul Frankel, Yujie Cui, Valerie Mira, Marian Llamas, Joann Hsu, Zeynep Büşra Zengin, Nicholas Salgia, Sabrina Salgia, Jasnoor Malhotra, Neal Shiv Chawla, Alex Chehrazi‐Raffle, Ramya Muddasani, John D. Gillece, Lauren Reining, J.M. Trent, Motomichi Takahashi, Kentaro Oka, Seiya Higashi, Marcin Kortylewski, Sarah K. Highlander, Sumanta K. Pal - Nature Medicine 2022 cited by 473

  2. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    Authors: David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Reeves, Mario Sznol, John D. Hainsworth, W. Kimryn Rathmell, Walter M. Stadler, Thomas E. Hutson, Martin Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo Danielli, Viktor Gruenwald, Toni K. Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault‐Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S. Chen, Priti S. Hegde, Christina Schiff, Gregg Fine, Thomas Powles - Nature Medicine 2018 cited by 1,250

  3. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

    Authors: Padmanee Sharma, Margitta Retz, Arlene O. Siefker‐Radtke, Ari David Baron, Andrea Necchi, Jens Bedke, Elizabeth R. Plimack, Daniel A. Vaena, Marc‐Oliver Grimm, Sergio Bracarda, José Ángel Arranz, Sumanta K. Pal, Chikara Οhyama, Abdel Saci, Xiaotao Qu, Alexandre Lambert, Suba Krishnan, Alex Azrilevich, Matthew D. Galsky - The Lancet Oncology 2017 cited by 1,744

  4. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

    Authors: Robert J. Motzer, Paul B. Robbins, Thomas Powles, Laurence Albigès, John B.A.G. Haanen, James Larkin, Xinmeng Jasmine Mu, Keith A. Ching, Motohide Uemura, Sumanta K. Pal, B. Yа. Alekseev, Gwénaëlle Gravis, Matthew T. Campbell, Konstantin Penkov, Jae‐Lyun Lee, Subramanian Hariharan, Xiao Wang, Weidong Zhang, Jing Wang, Aleksander Chudnovsky, Alessandra di Pietro, Amber C. Donahue, Toni K. Choueiri - Nature Medicine 2020 cited by 522

  5. CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma

    Authors: Sumanta K. Pal, Ben Tran, John B.A.G. Haanen, Michael E. Hurwitz, Adrian G. Sacher, Nizar M. Tannir, Lihua E. Budde, Simon J. Harrison, Sebastian Klobuch, Sagar S. Patel, Luís Meza, Mary‐Lee Dequéant, Anna Ma, Qiuling Ally He, Leah M. Williams, Alissa Keegan, Ellen B. Gurary, Henia Dar, Sushant Karnik, Changan Guo, Heidi Heath, Rachel R. Yuen, Phuong K. Morrow, Neeraj Agarwal, Samer A. Srour - Cancer Discovery 2024 cited by 139

  6. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial

    Authors: Sumanta K. Pal, Laurence Albigès, Piotr Tomczak, Cristina Suárez, Martin H. Voss, Guillermo de Velasco, Jad Chahoud, Anastasia Mochalova, Giuseppe Procopio, Hakim Mahammedi, Friedemann Zengerling, Chan Kim, Takahiro Osawa, Martín Ángel, Suyasha Gupta, Omara Khan, Guillaume Bergthold, Bo Liu, Melania Kalaitzidou, Mahrukh Huseni, Christian Scheffold, Thomas Powles, Toni K. Choueiri - The Lancet 2023 cited by 198

  7. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    Authors: Toni K. Choueiri, Bernard Escudier, Thomas Powles, Nizar M. Tannir, Paul N. Mainwaring, Brian I. Rini, Hans J. Hammers, Frede Donskov, Bruce J. Roth, Katriina Peltola, Jae‐Lyun Lee, Daniel Y.C. Heng, Manuela Schmidinger, Neeraj Agarwal, Cora N. Sternberg, David F. McDermott, Dana T. Aftab, Colin Hessel, Christian Scheffold, Gisela Schwab, Thomas E. Hutson, Sumanta K. Pal, Robert J. Motzer - The Lancet Oncology 2016 cited by 939

  8. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial

    Authors: Sumanta K. Pal, Robert G. Uzzo, José A. Karam, Viraj A. Master, Frede Donskov, Cristina Suárez, Laurence Albigès, Brian I. Rini, Yoshihiko Tomita, Ariel Galapo Kann, Giuseppe Procopio, Francesco Massari, Matthew R. Zibelman, I. Antonyan, Mahrukh Huseni, Debasmita Basu, Bo Ci, William Leung, Omara Khan, Sarita Dubey, Axel Bex - The Lancet 2022 cited by 230

  9. Stool Microbiome Profiling of Patients with Metastatic Renal Cell Carcinoma Receiving Anti–PD-1 Immune Checkpoint Inhibitors

    Authors: Nicholas Salgia, Paulo Gustavo Bergerot, Manuel Caitano Maia, Nazlı Dizman, Joann Hsu, John D. Gillece, Megan Folkerts, Lauren Reining, Jeffrey M. Trent, Sarah K. Highlander, Sumanta K. Pal - European Urology 2020 cited by 192

  10. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

    Authors: Toni K. Choueiri, Robert J. Motzer, Brian I. Rini, John B.A.G. Haanen, Matthew T. Campbell, B. Venugopal, Christian Kollmannsberger, Gwénaëlle Gravis, Mamoru Uemura, J.L. Lee, Marc‐Oliver Grimm, Howard Gurney, Manuela Schmidinger, James Larkin, Michael B. Atkins, Sumanta K. Pal, J. Wang, Mariangela Mariani, S. Krishnaswami, Paul Cislo, A. Chudnovsky, Camilla Fowst, Bo Huang, Alessandra di Pietro, Laurence Albigès - Annals of Oncology 2020 cited by 461

  11. Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology

    Authors: Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Sam S. Chang, Tracy M. Downs, Jason A. Efstathiou, Terence W. Friedlander, Richard E. Greenberg, Khurshid A. Guru, Thomas Guzzo, Harry W. Herr, Jean Hoffman‐Censits, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Jeff M. Michalski, Jeffrey S. Montgomery, Lakshminarayanan Nandagopal, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker‐Radtke, Jonathan D. Tward, Jonathan L. Wright, Lisa A. Gurski, Alyse Johnson-Chilla - Journal of the National Comprehensive Cancer Network 2020 cited by 628

  12. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

    Authors: Sumanta K. Pal, Catherine M. Tangen, Ian M. Thompson, Naomi Balzer-Haas, Daniel J. George, Daniel Y.C. Heng, Brian Shuch, Mark N. Stein, Maria Tretiakova, Peter A. Humphrey, Adebowale Adeniran, Vivek Narayan, Georg A. Bjarnason, Ulka N. Vaishampayan, Ajjai Alva, Tian Zhang, Scott Cole, Melissa Plets, John Wright, Primo N. Lara - The Lancet 2021 cited by 279

  13. Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival

    Authors: Shaan Dudani, Guillermo de Velasco, J. Connor Wells, Chun Loo Gan, Frede Donskov, Camillo Porta, Anna Paola Fraccon, Felice Pasini, Jae‐Lyun Lee, Aaron R. Hansen, Georg A. Bjarnason, Benoit Beuselinck, Sumanta K. Pal, Takeshi Yuasa, Nils Kroeger, Ravindran Kanesvaran, M. Neil Reaume, Christina Canil, Toni K. Choueiri, Daniel Y.C. Heng - JAMA Network Open 2021 cited by 299

  14. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

    Authors: Matthew D. Galsky, Siamak Daneshmand, Sudeh Izadmehr, Edgar Gonzalez‐Kozlova, Kevin Chan, Sara Lewis, Bassam El Achkar, Tanya B. Dorff, Jeremy Cetnar, Brock O Neil, Anishka D'souza, Ronac Mamtani, Christos E. Kyriakopoulos, Tomi Jun, Mahalya Gogerly-Moragoda, Rachel Brody, Hui Xie, Kai Nie, Geoffrey Kelly, Amir Horowitz, Yayoi Kinoshita, Ethan Ellis, Yohei Nose, Giorgio Ioannou, Rafael Cabal, Diane M. Del Valle, G. Kenneth Haines, Li Wang, Kent W. Mouw, Robert Samstein, Reza Mehrazin, Nina Bhardwaj, Menggang Yu, Qianqian Zhao, Seunghee Kim‐Schulze, Robert Sebra, Jun Zhu, Sacha Gnjatic, John P. Sfakianos, Sumanta K. Pal - Nature Medicine 2023 cited by 133

  15. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study

    Authors: Saro H. Armenian, Lanfang Xu, Bonnie Ky, Can‐Lan Sun, Leonardo Farol, Sumanta K. Pal, Pamela S. Douglas, Smita Bhatia, Chun Chao - Journal of Clinical Oncology 2016 cited by 544

  16. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

    Authors: Hedyeh Ebrahimi, Nazlı Dizman, Luís Meza, Jasnoor Malhotra, Xiaochen Li, Tanya B. Dorff, Paul Frankel, Marian Llamas-Quitiquit, Joann Hsu, Zeynep Büşra Zengin, Marice Alcantara, Daniela V. Castro, Benjamin Mercier, Neal Shiv Chawla, Alex Chehrazi‐Raffle, Regina Barragán-Carrillo, Salvador Jaime‐Casas, Ameish Govindarajan, John D. Gillece, Jeffrey M. Trent, Peter P. Lee, Thomas P. Parks, Motomichi Takahashi, Atsushi Hayashi, Marcin Kortylewski, J. Gregory Caporaso, Keehoon Lee, Abhishek Tripathi, Sumanta K. Pal - Nature Medicine 2024 cited by 82

  17. Melanoma and microbiota: Current understanding and future directions

    Authors: Bertrand Routy, Tanisha Jackson, Laura Mählmann, Christina K. Baumgartner, Martin J. Blaser, Allyson L. Byrd, Nathalie Corvaı̈a, Kasey L. Couts, Diwakar Davar, Lisa Derosa, Howard C. Hang, Geke A.P. Hospers, Morten L. Isaksen, Guido Kroemer, Florent Malard, Kathy D. McCoy, Marlies Meisel, Sumanta K. Pal, Ze’ev A. Ronai, Eran Segal, Gregory D. Sepich‐Poore, Fyza Y. Shaikh, Randy F. Sweis, Giorgio Trinchieri, Marcel R.M. van den Brink, Rinse K. Weersma, Katrine Whiteson, Liping Zhao, Jennifer L. McQuade, Hassane M. Zarour, Laurence Zitvogel - Cancer Cell 2023 cited by 78

  18. PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial

    Authors: Tanya B. Dorff, M. Suzette Blanchard, Lauren Adkins, Laura Luebbert, Neena A. Leggett, Stephanie N. Shishido, Alan Macias, Marissa Morales Del Real, Gaurav Dhapola, Colt A. Egelston, John P. Murad, Reginaldo Cruz Alves Rosa, Jinny Paul, Ammar Chaudhry, Hripsime Martirosyan, Ethan Gerdts, Jamie R. Wagner, Tracey Stiller, Dileshni Tilakawardane, Sumanta K. Pal, Catalina Martínez, Robert E. Reiter, Lihua E. Budde, Massimo D’Apuzzo, Peter Kühn, Lior Pachter, Stephen J. Forman, Saul J. Priceman - Nature Medicine 2024 cited by 116

  19. Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study

    Authors: Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante, Brian I. Rini, David F. McDermott, Lionel D. Lewis, Martin H. Voss, Padmanee Sharma, Sumanta K. Pal, Albiruni R. Abdul Razak, Christian Kollmannsberger, Daniel Y.C. Heng, Jennifer L. Spratlin, M. Brent McHenry, Asim Amin - Journal of Clinical Oncology 2017 cited by 508

  20. Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers

    Authors: Christopher J.D. Wallis, Mohit Butaney, Raj Satkunasivam, Stephen J. Freedland, Sandip Pravin Patel, Omid Hamid, Sumanta K. Pal, Zachary Klaassen - JAMA Oncology 2019 cited by 302

  21. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study

    Authors: Brian I. Rini, Sumanta K. Pal, Bernard Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, David F. McDermott - The Lancet Oncology 2019 cited by 257

  22. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study

    Authors: Sumanta K. Pal, Bradley McGregor, Cristina Suárez, Che-Kai Tsao, William Kelly, Ulka Vaishampayan, Lance Pagliaro, Benjamin L. Maughan, Yohann Loriot, Daniel Castellano, Sandy Srinivas, Rana R. McKay, Robert Dreicer, Thomas Hutson, Sarita Dubey, Scott Werneke, Ashok Panneerselvam, Dominic Curran, Christian Scheffold, Toni K. Choueiri, Neeraj Agarwal - Journal of Clinical Oncology 2021 cited by 140

  23. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

    Authors: Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel, Jean‐Christophe Pignon, Miriam Ficial, Osvaldo Arén Frontera, Saby George, Thomas Powles, Frede Donskov, Michael R. Harrison, Philippe Barthélémy, Scott S. Tykodi, Judit Kocsis, Alain Ravaud, Jerónimo Rafael Rodríguez‐Cid, Sumanta K. Pal, André M. Murad, Yuko Ishii, Shruti Shally Saggi, M. Brent McHenry, Brian I. Rini - Clinical Cancer Research 2020 cited by 242

  24. The Microbiome and Genitourinary Cancer: A Collaborative Review

    Authors: Mark C. Markowski, Stephen A. Boorjian, Jeremy P. Burton, Noah M. Hahn, Molly A. Ingersoll, Saman Maleki Vareki, Sumanta K. Pal, Karen S. Sfanos - European Urology 2019 cited by 176